French bone marrow transplant (BMT) centers participated in a prospective randomized trial comparing two conditioning regimens for patients with chronic myeloid leukemia transplanted in first chronic phase with an HLA identical sibling donor. A total of 120 consecutive patients were randomized to receive either 120 mg/kg of cyclophosphamide followed by total body irradiation (CY-TBI; n = 55) or 16 mg/kg of busulfan followed by 120 mg/kg of CY (BU-CY; n = 65). Two different TB1 regimens were used. Thirteen patients received a 10-Gy singledose TB1 (SDTBI), and 42 received a fractionated TB1 (FTBI). Median time between diagnosis and BMT was 315 days. Overall 5-year actuarial survival was 62.9% (65.8% f 12.5% for CY-TB1 and 60.6 f 11.7% for BU-CY; P = .5), and overall disease-free survival was 55% (51yo f 14% for CY-TB1 and 59.1yo f 11.8% for BU-CY; P = .75). All patients conditioned with CY-TB1 experienced sustained engraftment; in contrast, 4 of 65 patients conditioned with BU-CY rejected the graft ( P = .18). There was no significant statistical difference between the two groups regarding transplant-related mortal-
LLOGENEIC BONE MARROW tranplantation (BMT)
after preparation with high-dose cyclophosphamide (CY) and total body irradiation (TBI) is a highly efficient therapy for patients suffering from chronic myeloid leukemia (CML).'" In our experience: as in that of other groups, if BMT is performed during the first chronic phase, the relapse rate may not go beyond 10% provided that a non-T-celldepleted graft is used. However, BMT may fail because of transplant-related death, for which total radiation dose was identified as one of the most significant risk factor^.^.^ In addition, the use of TB1 has also been associated with the development of a variety of long-term complications including secondary malignancies, cataracts, impaired growth, and endocrine dysfunction." Therefore, radiation-free conditioning regimens have been investigated. The association of busulfan (BU) and CY was reported to give a similar or even higher leukemic ablation than regimens including TBI."-'* Nevertheless, overall results and long-term effects of BU-CY and CY-TB1 regimens for patients with CML had not been prospectively evaluated so far. Therefore, as had other groups," we decided to randomly evaluate CY-TB1 regimen versus BU-CY regimen. We report results of 120 consecutive patients who entered a national prospective trial initiated in 1988 by the French BMT Group (SociCt6 Franpise de Greffe de Moelle). This study compares the outcome of patients with CML in first chronic phase receiving allogeneic BMT prepared with CY (120 mgkg) and either TB1 or BU (16 A m g w .
PATIENTS AND METHODS

Patients.
To be entered in ths trial, patients had to meet the following eligibility criteria: (1) (29yo for CY-TB1 and 38% for BU-CY; P = .U). So far, with a median follow up of 42 months, 11 patients have relapsed; 9 relapses occurred after CY-TBI, mostly after FTBl (8 of 9) and 2 after BU-CY (P = .02). The actuarial risk of relapse was 4.4% f 6.7% after BU-CY, 11.1% f 20.8% after SDTBI, and 31.3% f 18.1% after FTBl ( P = .039). In addition, independently of the conditioning regimen, the increase of posttransplant immunosuppression in 16 patients with an antiinterleukin-2 receptor monoclonal antibody (MoAb) in addition to a short course of methotrexate and cyclosporine was shown to increase the actuarial risk of relapse (57% f 30% with MoAb ~9 % f 7.3Y0 without MoAb; P = .001). We conclude that BU is an acceptable alternative to TB1 for patients with chronic myeloid leukemia in first chronic phase receiving BMT from HLA identical sibling donors. Both BU-CY and CY-TB1 regimens gave similar transplant-related mortality, and the antileukemic efficiency of BU-CY regimen was either similar or even higher than that of CY-TBI.
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being in first chronic phase, defined as normal or nearly normal blood counts, no significant symptoms, and no significant organomegaly; ( 3 ) having an HLA-identical, negative mixed lymphocyte culture sibling donor.
The protocol was reviewed by the ethical committee of University of Saint Louis-Lariboisibre, and consent was obtained from all patients or legal guardians.
Between Condirioning regimen. All patients received 60 m a g CY intravenously on each of 2 consecutive days. For 65 patients (BU-CY group), this was preceded by the administration of BU. BU was administered orally at 1 mg/kg/dose every 6 hours over 4 consecutive days for a total dose of 16 m a g , adjusted to the real body weight. For 55 patients (CY-TB1 group), CY was followed by TBI. The irradiation protocol differed from one center to another, according to local facilities. Thirteen patients received a IO-Gy single-dose (SD) irradiation. The dose rate was 3 cGy per minute, and the lungs were shielded to a lung dose of 8 Gy. Forty-two patients received a fractionated (F) TB1 to a median dose of 12 Gy (range, 11 to 12 Gy). Among these 42 patients, 30 received the same FTBI regimen (12 Gy in 6 fractions of 2 Gy twice daily over 3 days), with a median dose rate of 8 cGy per minute (range, 5 to 25 cGy) and a median lung dose of 10 Gy (range, 8 to 11 Gy). Fractionation schemes varied for 12 patients. One patient received hyperfractionated TB1 (12 Gy in 24 fractions of 0.5 Gy over 3 days with a lung dose of 7 Gy); 7 patients received 12 Gy in 3 fractions of 4 Gy over 3 days, and 4 patients received 11 Gy in 5 fractions of 2.2 Gy over 5 days, with a lung dose of 8 Gy. Finally, all patients treated with either SDTBI or R B I had a lung shielding to a median lung dose of 8.8 Gy (range, 7 to 11 Gy). Genoidentical unmanipulated BM was infused 24 to 36 hours after the last day of conditioning regimen.
Posttransplant immunosupression.
All patients received shortcourse methotrexate (MTX) and cyclosporine (CSA) according to the Seattle group prot~col.'~ Intravenous CSA was substituted by an oral dose when tolerated, and the dose was adjusted according to CSA blood levels. In addition, 3 1 patients were included in a multicentric randomized trial of prophylaxis of graft-versus-host disease (GVHD), studying the efficacy of the adjunction of an anti-interleukin-2 receptor monoclonal antibody (anti-P55 MoAb) to the combination of MTX and CSA.'' This trial involved seven centers and included patients with acute or chronic leukemias in first remission or in first chronic phase. Therefore, 31 patients with CML in first chronic phase were included in both trials.
A total of 16 patients were randomized to receive anti-P55 MoAb from day 1 to day 28, in addition to MTX and CSA, and 15 patients were entered in the control group (MTX and CSA). Among these 16 patients treated with prophylactic MoAb, 8 were conditioned with CY-FTBI and 8 with BU-CY.
Relapse. The monitoring strategy to evaluate the occurrence of relapse differed from one center to another. In our analysis, endpoint for relapse was persistent cytogenetic relapse, ie, the detection of Ph-positive metaphases in the BM after at least 2 months post-BMT, persisting in subsequent cytogenetic analysis.
Starisrical analysis. Actuarial survival, relapse, and relapse-free survival curves were obtained using Kaplan-Meier product-limit estimates. Comparison of survival curves was based on the log-rank test. Endpoint for survival was the date the patient was last contacted before November 1993. The two variables significantly associated with a higher risk of relapse in univariate analysis, ie, the conditioning regimen and the prophylaxis of GVHD, were entered in a rnultivariate analysis using a Cox model. Our analyses were performed on an IBM personal computer (Paris, France) with BMDP statistical software.
RESULTS
Patients' characteristics at time of transplant are summarized in Table 1 . No significant statistical difference existed Table 2 shows the outcome of the graft, including engraftment, toxicity of the two conditioning regimens, relapse, GVHD, overall and disease-free survival (DFS). Relapse. So far, the relapse rate is low (11 of 120). Nevertheless, there was a significant statistical difference between the two conditioning regimens, because 9 relapses occurred after CY-TB1 and 2 after BU-CY ( P = .02). 12.5% after CY-TB1 and 60.6% 2 11.7% after BU-CY; P = S ) , and overall DFS was 55% (51% ? 14% after CY-TB1 and 59.1% ? 11.8% after BU-CY; P = .75).
Engraftment. Engraftment was defined as
Time interval from diagnosis to transplant. Three quarters of the patients were transplanted within the first year of diagnosis; actuarial survival is not significantly different whether the transplant was performed within the first year or later (65.5% v 55.3%; P = S ) . with in vitro T-cell depletion of the BM after preparation with BU-CY 120 appears to be associated with a higher incidence of engraftment failure than that after preparation with CY-TBI.I6"' Furthermore, Blaise et al" have shown in a randomized trial in patients with acute myeloid leukemia (AML) in first remission, receiving allogeneic BMT after a preparation with CY-TB1 or BU-CY 120, that a higher relapse rate and a decreased survival were associated with BU-CY 120 regimen. Thus, it is not clear whether the immunosupressive and antileukemic capacity of BU-CY 120 is as great as that of standard CY-TB1 regimens.
DISCUSSION
BU-CY regimen was initially described by
Our multicentric trial was designed to compare prospectively the chemotherapeutical preparation consisting of BU 16 mgkg and CY 120 mgkg (BU-CY 120) versus the "standard" conditioning regimen with CY 120 mgkg and TB1 (CY-TBI) in patients with CML in first chronic phase. Moreover, there were two additional variants of the conditioning regimen. One is the use of two different TB1 regimens, ie, SDTBI versus R B I , and the other is the use of MoAb for GVHD prophylaxis in a subpopulation of patients. Both of these variations were shown to be important for the outcome on influencing the relapse rate.
In our study, overall results in survival and DFS for the 2 groups of patients, treated with either BU-CY 120 or CY-TBI, are not significantly different. This finding matches the recently published results of a unicentric randomized trial conducted by Clift et all9 comparing BU-CY 120 with CY-TB1 in patients with CML in first chronic phase that showed no significant statistical differences between the treatment arms regarding survival or nonrelapse mortality. Nevertheless, in our trial, we observed two differences between the two groups of patients, (1) an unexpected occurrence of graft failure after BU-CY and (2) an increased risk of relapse after CY-TBI, especially FTBI.
Previously published results did not show an increase in graft failure after BU-CY regimen, as long as an unmanipulated HLA identical related BM was used, In a multi-institutional study, primary failure of engraftment occurred in only 3 of 28 1 patients with AML (n = 127): ' acute lymphoblastic DEVERGIE ET AL leukemia (n = 39)," or CML (n = 115).*' Among the 142 patients described by Clift et al," all patients achieved sustained engraftment, and late rejection did not occurr. On the contrary, preliminary analysis of our randomized trial" showed a borderline difference in transplant rejection rate between the two groups. Rejection is an extremely rare event for patients grafted for acute or chronic leukemias and conditioned with a TB1 regimen. Nevertheless, graft failure can be observed after a T-cell-depleted BMT and is associated with an increased risk of relapse.24 Thus, the occurrence of 4 rejections in the BU-CY group led us to fear for an increased risk of late relapses. As a matter of fact, it was not the case.
On the contrary, with a median follow up of 42 months, there was a higher risk of relapse after TB1 . This difference was observed only in patients who had received a fractionated irradiation and not for patients conditioned with an SDTBI. Finally, the antileukemic efficacy of BU-CY 120 regimen was at least as good as conventional CY-TB1 regimen (SDTBI) and was better than CY-FTBI regimen. The impact of fractionation of TB1 on the relapse rate for patients tranplanted for CML in first chronic phase is discussed, and discordant results have been reported. In a review of the literature concerning TB1 fractionation,2s including both acute and chronic leukemias, the same relapse rate was found for SDTBI (15.8%) and for FTBI (15.7%) used as conditioning regimen before non-T-cell-depleted BMT. A report from the International Bone Marrow Transplant Registry did not show TB1 fractionation to be a significant parameter for relapse after BMT for CML in chronic phase.5 On the contrary, in a previous retrospective study from the French Registry on 180 patients with CML who received an unmanipulated BM graft after a CY-TB1 regimen, we reported a significant increase of relapse risk after FTBI compared with SDTBI.26 Thus, it is suggested that the fractionation's sparing effect for extramedullary organs, especially when associated to systematic lung shielding, could be offset by a less effective leukemic cell kill, in any case for first chronic phase CML. Nevertheless, the statistical power of our study is For personal use only. on November 11, 2017. by guest www.bloodjournal.org From limited because of the low number of relapse events. Although the RR of relapse for patients receiving CY-TB1 is 4.1 against the standard of patients receiving BU-CY, because the lower limit of the standard deviation includes l .W, the relationship is, therefore, probably weak.
In our present study, another variable was shown to be correlated with relapse incidence, ie, prophylaxis of acute GVHD with anti-P55 MoAb. Multivariate analysis showed that prophylaxis of GVHD was an independent significant risk factor for relapse. Thus, as it has been established for T-cell it is suggested that an increase of posttransplant immunosuppression could be followed by an increased risk of relapse for patients with CML.
In this trial, the early transplant toxicity and the transplantrelated mortality were comparable when using either CY-TB1 or BU-CY. This finding is comparable with the results of another randomized trial comparing BU-CY with CY-TBI, conducted by the Nordic Bone Marrow Transplantation Group:' in which relapse-free survival and transplant-related mortality were similar in the two groups for patients with early disease. In the Seattle t r i a l , I g the BU-CY regimen was tolerated even better than the CY-TB1 regimen.
To conclude, BU-CY 120 compared with CY-TB1 appears to be possibly associated with a higher incidence of graft rejection, indicating that the immunosuppressive capacity of this regimen could be insufficient; nevertheless, the difference is not significantly different. In this study, in contrast with results previously published on AML patients," leukemic cell kill of BU-CY 120 regimen appears to be sufficient, maybe because the probability of relapse in first chronic phase CML is much lower than in AML. Finally, overall results show that BU-CY 120 can be favourably compared with classical CY-TB1 regimen.
